Quick Dispatch:
Your soul trial oral semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an oral #GLP1RA 14% reduction in MACE with oral semaglutide among 9,650 people with T2D and established orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an oral #GLP1RA 14% reduction in MACE with oral semaglutide among 9,650 people with T2D and established ships.
Need Help?
Questions about soul trial oral semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an oral #GLP1RA 14% reduction in MACE with oral semaglutide among 9,650 people with T2D and established, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an oral #GLP1RA 14% reduction in MACE with oral semaglutide among 9,650 people with T2D and established in your area.
European
21.66
The SOUL trial (Semaglutide Cardiovascular Outcomes Trial) was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial that enrolled 9,650 patients aged 50 years or older with
22.96
ACC 2026
27.49
Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
29.00
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
26.89
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events
23.45
Oral semaglutide (Rybelsus®) receives FDA approval for the treatment of type 2 diabetes
29.83
